SLC5A2 and type 2 diabetes mellitus: The selective sodium-glucose co-transporter-2 inhibitors (SGLT2) canagliflozin (cana), dapagliflozin (dapa), ertugliflozin (ertu), and empagliflozin (empa) are approved as therapeutic glucose-lowering agents for the treatment of type 2 diabetes patients [1,2,3,4,5,6,7,8].